# CLINICAL OBSERVATIONS ON CANCER PATTERNS AT THE NON-WHITE HOSPITAL BARAGWANATH, JOHANNESBURG, 1948-1964* 

M. A. Robertson, M.A., M.B., B.Chir. (Cantab), L.R.C.P. (Lond.), F.R.C.S. (Eng.), Cancer Research Unit of the National Cancer Association of South Africa, South African Institute for Medical Research, Johannesburg

The fundamental work undertaken by Higginson and Oettlé ${ }^{1}$ on the cancer incidence in the Bantu and Cape Coloured races covered the years 1953-1955. In addition the work carried out by the late Dr Oettlé ${ }^{2}$ in subsequent years has laid the foundations of our knowledge of the cancer incidence in the Bantu of Southern Africa. In 1965 it was decided to extend the scope of the Bantu survey and analyse the total admissions to the Baragwanath nonWhite Hospital from June 1948 until December 1964.

The object of this publication is to stress certain clinical observations on the distribution of cancer in the nonWhite patient and some changes in cancer incidence occurring at this hospital during the past 17 years.

Situated on the outskirts of Johannesburg, Baragwanath Hospital was transformed from a military to a civilian non-White hospital in June 1948. Approximately 800 beds were available when the hospital opened, and the number of beds has increased steadily to the stage where, in 1967, more than 2,100 beds were in constant use. In December 1967, after excluding medical, orthopaedic, paediatric and maternity beds, it was found that there were approximately 700 adult surgical beds, with an equal sex distribution.

The population served is the civilian population of Johannesburg excluding the Reef mines which have their own medical services. There are in addition 3 other small non-White hospitals in the Johannesburg area. The Baragwanath Hospital has several highly specialized departments and some patients are referred from hospitals of the Reef towns situated within 70 miles of Johannesburg, and, in addition, some patients are transferred from outlying hospitals of the Transvaal as rural admissions. In this series $88.7 \%$ of patients were from the Johannesburg area, $8.2 \%$ from local Reef towns, $2.3 \%$ were rural admissions and $0.8 \%$ were unspecified. The local population served is approximately 600,000 , but cases are referred from all the southern Transvaal hospitals, including mission hospitals, thus increasing the service for some specialized treatments to possibly $3 \frac{1}{2}$ million.

The total number of admissions included maternity, paediatric, gynaecological, medical and surgical cases, as well as readmissions. These admissions have doubled in under 14 years. The 3 categories of patients consisted of $95.0 \%$ Bantu; $4.0 \%$ Coloured; $0.7 \%$ Asiatics and $0.3 \%$ 'other' (not specified).

## METHOD OF SURVEY

A preliminary sample analysis was undertaken of total admissions to the wards of all cases for two separate months in 1964, as a guide to the variety of admissions.

Table I analyses the total admission of cases from Johannesburg, the Reef towns and the rural areas for 2 sample months in 1964, as a basis for comparison. Distribution in hospital by sex, age and category of complaint has been noted.

However, owing to the growth of population served,

[^0]enlargement of hospital accommodation and variables of accidents and other reasons, it was decided to relate the sites and types of cancer to the percentage of total annual cancer admissions in order to give comparable annual figures.

TABLE I. ADMISSIONS TO BARAGWANATH HOSPITAL: ANALYSIS BY MONTHLY SAMPLE


The survey itself included the examination of the filing system at the registry of Baragwanath Hospital and the extraction of all relevant bed letters since 1948. With the assistance of the special filing system of the registry, it was possible to eliminate maternity and other non-relevant material from the inspection. The cancer cases were extracted, and history details after classification were
correlated with other earlier surveys including one by Higginson and Oettle in 1948-1953, and a further 1953. 1955 survey by Oettlé ${ }^{2}$ used for analysing specific sites, types, rates and ratios of the various racial groups. This extraction was continued for all hospital records until the end of 1964. A précis was made of each case and then completed by the addition of the pathological reports, by perusal of the records at the South African Institute for Medical Research from 1948 onwards, and from the Baragwanath Branch established in 1954. These included the special departments of neuropathology and clinical pathology and postmortem examination reports. All pathology records were examined and included if relevant. Finally, all cases were correlated to exclude dual recording in different years and were subdivided under the code numbers of the International Classification of Diseases for each of the 17 years. ${ }^{3}$

TABLE II. TOTAL ADMISSIONS TO BARAGWANATH HOSPITAL. 1948-1964

| $\begin{aligned} & \text { Year } \\ & 1948 \end{aligned}$ | Total admissions | Total No. of cancers |  |  | Cancer as \% of |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | Total cancers | Male | Female | Total admissions | Male | Female |
|  | Not |  |  |  |  |  |  |
| 1949 | available | 83 | 44 | 39 | - | $53 \cdot 0$ | $47 \cdot 0$ |
|  | Not |  |  |  |  |  |  |
|  | available | 185 | 85 | 100 | - | $45 \cdot 9$ | $54 \cdot 1$ |
| 1950 | Not |  |  |  |  |  |  |
|  | available | 233 | 119 | 114 |  | 51.1 | $48 \cdot 9$ |
| 1951* | 26,110 | 240 | 129 | 111 | 0.923 | $53 \cdot 7$ | $46 \cdot 3$ |
| 1952 | 29,530 | 331 | 182 | 149 | 1-120 | $55 \cdot 0$ | $45 \cdot 0$ |
| 1953 | 29,620 | 392 | 195 | 197 | 1.323 | $49 \cdot 7$ | $50 \cdot 3$ |
| 1954 | 33,470 | 353 | 161 | 192 | 1.054 | $45 \cdot 6$ | $54 \cdot 4$ |
| 1955 | 37,616 | 348 | 168 | 180 | 0.925 | $48 \cdot 3$ | $51 \cdot 7$ |
| 1956 | 37,756 | 420 | 205 | 215 | 1-112 | $48 \cdot 8$ | $51 \cdot 2$ |
| 1957 | 39,671 | 481 | 254 | 227 | 1. 212 | $52 \cdot 8$ | $47 \cdot 2$ |
| 1958 | 41,607 | 491 | 249 | 242 | 1. 180 | $50 \cdot 7$ | $49 \cdot 3$ |
| 1959 | 47,678 | 561 | 283 | 278 | 1.176 | $50 \cdot 4$ | $49 \cdot 6$ |
| 1960 | 46,842 | 594 | 305 | 289 | 1. 268 | $51 \cdot 3$ | $48 \cdot 7$ |
| 1961 | 48,599 | 678 | 364 | 314 | 1.395 | $53 \cdot 7$ | $46 \cdot 3$ |
| 1962 | 52,974 | 744 | 403 | 341 | 1.404 | $54 \cdot 2$ | $45 \cdot 8$ |
| 1963 | 51,936 | 793 | 439 | 354 | 1. 526 | 55.4 | $44 \cdot 6$ |
| 1964 | 55,612 | 890 | 508 | 382 | 1.600 | $57 \cdot 1$ | $42 \cdot 9$ |
|  | 579,021 | 7,817 | 4,093 | 3,724 | 1. 263 | $52 \cdot 4$ | $47 \cdot 6$ |

- International Code started in 1951. Total admissions include maternity, paediatrics, ophthalmic, medical and surgical male and female.

Table II indicates the total number of admissions to the hospital, the total cancer cases and the proportions of males and females of these cancer cases expressed as percentages of total and of cancer admissions. This table also shows a steady increase of cancer admissions compared with admissions as a whole, with an average of $1.263 / 100$. The over-all gradual increase in male and female admission over the past 8 years should be noted, but may possibly be accounted for by the increase in cases of oesophageal cancer, and the provision of specialist services. During the period 1957-1964 the percentage of male cases consistently exceeded that of females. This too may be accounted for by the steady increase in cases of oesophageal cancer in males.

There were 7,817 cases registered as first admissions. consisting of 4,093 males and 3,724 females, subsequent admissions being recorded with the first as one cancer case. Missing or inadequate bed letters, mainly in the earlier years, were mostly traced through pathology records, but full clinical details were in these cases occasionally incomplete. The diagnosis was proved histologically in $84 \%$ of cases and in the remaining $16 \%$ the diagnosis was made on clinical evidence. Many of the latter category were very advanced, moribund and clinically obvious, and not fit for any radical treatment. The records at the clinical laboratory were unavailable for leukaemias, and final correlation of these with bed letters was not possible, so that these cases were slightly underestimated.

Intra-epithelial carcinoma of the skin and conjunctiva, carcinoma in situ in the oesophagus and cervix, and other conditions that are known to be precancerous were excluded, on the grounds that they were not invasive. These transitional cases, between acceptance and rejection, would seem to warrant greater histochemical study as a link between cancer and normality. There were 13 cases which had dual cancers and one case with triple primary cancer pathology.

The sources of information, checks from other surveys, the pathology records and other corroborative data indicated that the survey was sufficiently complete for adequate analysis and that very few cases had been unaccounted for.

Table III shows the incidence of multiple primary cancer

TABLE iII. MULTIPLE PRIMARY CANCERS BY SEX, SITE, AGE AND TRIBE BY YEAR

| Year | Sex | Site I | Site II | Age (yrs) | Tribe |
| :---: | :---: | :---: | :---: | :---: | :---: |
| 1950 | M | Oesophagus: mod. diff. sq. Ca. | Stomach: adenocarcinoma | 38 | Nyasa |
| 1952 | Albino |  |  |  |  |
|  | M | Ear: well-diff. sq. Ca. | Lip: mod. diff. sq. Ca. | 30 | Zulu |
| 1953 | M | Gum: spindle-cell sarcoma | Abdominal wall: angiosarcoma | 70 | Sotho |
| 1953 | M | Cervical lymph gland: meta. sq. Ca. Primary oesophagus | Bladder: proved transitional-cell Ca . | 52 | Sotho |
| 1954 | F | Dermato-fibrosarcoma | (2) Skin: metastatic adenocarcinoma. <br> (3) Also neurofibrosarcoma of abdo- |  |  |
| 1956 | F | Cervix: grade II sq. Ca. | Vulva: condylomata with areas of carcinomatous degeneration | 58 44 | Xhosa Sotho |
| 1957 | M | Bladder: poorly diff. sq. Ca. | Haemangiosarcoma of skin | 65 | Xhosa |
| 1959 | F | Hysterectomy: cervix sq. Ca. | Ovary: cystadenocarcinoma | 50 | Swazi |
| 1960 | F | Stomach (linitis plastica) | Breast | 74 | Sotho |
| 1960 | M | Stomach: colloidal Ca. | Liver: malig. hep. | 44 | Zulu |
| 1960 | F | Cervix: adenocarcinoma | Breast: some adenocarcinoma, som? colloidal Ca . | 56 | Coloure |
| 1961 | F | Corpus: adenocarcinoma | Ovary: cystadenocarcinoma | 41 | Tswana |
| 1964 | M | Malignant lymphoma | Kaposi's sarcoma | 80 | Rolong |

confirmed by histology occurring at the same time, except for one case in 1953 when the bladder and oesophagus cancers were diagnosed at an interval of 18 months.

Table IV gives the annual admissions relating to each site, expressed as a percentage of total admissions for that year. It indicates a marked rise in the rate of carcinoma of the oesophagus in the last 7 years, although malignancies of the stomach and buccal cavity remained relatively static. Malignant hepatomas were less frequent than expected. Carcinoma of the lung showed a slight increase, but the increase did not affect females to the
same extent as males. Carcinoma of the cervix was shown to be gradually decreasing in proportion to other cancers, although actual numbers of cases were still increasing. Cancer of bone and all the lymphatic and haematopoietic neoplasms showed a decrease in relative incidence.

Table V is a summary of the total cancer cases and demonstrates the differing incidence by sex at all sites.

Table VI shows these apparently different rates between male and female to be real in terms of both Transvaal population based on the 1960 census and hospital admissions over 17 years.

TABLE IV. 'CHANGING' PATTERN OF CANCER AT BARAGWANATH HOSPITAL EXPRESSED AS A PERCENTAGF OF TOTAL CANCER ADMISSIONS FOR EACH YEAR FOR 17 YEARS

|  |  | 1948 | 1949 | 1950 | 1951 | 1952 | 1953 | 1954 | 1955 | 1956 | 1957 | 1958 | 1959 | 1950 | 1951 | 1952 | 1963 | 1964 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Total No. of admission hospital |  | $\begin{aligned} & \text { Un- } \\ & \text { known } \end{aligned}$ | $\begin{gathered} \text { Un- } \\ \text { known } \end{gathered}$ | $\begin{gathered} \text { Un- } \\ \text { known } \end{gathered}$ | 26.110 | 29,530 | 29,620 | 33,470 | 37.616 | 37,756 | 39,671 | 41,607 | 47,678 | 46,842 | 48,599 | 52,974 | 51,936 | 55,612 |
| Total cancer cases in t admissions |  | 83 | 185 | 233 | 240 | 331 | 392 | 353 | 348 | 420 | 481 | 491 | 561 | 594 | 678 | 744 | 793 | 890 |
| Annual cancer cases as | M | $53 \cdot 0$ | $45 \cdot 9$ | 51.1 | $53 \cdot 7$ | 55.0 | $49 \cdot 7$ | $45 \cdot 6$ | $48 \cdot 3$ | $48 \cdot 8$ | 52-8 | 50.7 | 50.4 | 51.3 | $53 \cdot 7$ | $54 \cdot 2$ | 55.4 | $57 \cdot 1$ |
| $\%$ by sex | F | 47.0 | 54.1 | $48 \cdot 9$ | $46 \cdot 3$ | $45 \cdot 0$ | 50.3 | 54-4 | 51.7 | $51 \cdot 2$ | 47-2 | 49.3 | $49 \cdot 6$ | $48 \cdot 7$ | 46.3 | $45 \cdot 8$ | $44 \cdot 6$ | $42 \cdot 9$ |
| Buccal cavity and pha- | M | 12.06 | 3.78 | $5 \cdot 15$ | $4 \cdot 58$ | 6.34 | 4.08 | 4.81 | 3-16 | 3.80 | 4.15 | 5.09 | 4.81 | 3.87 | $4 \cdot 12$ | 3.09 | 4.53 | 5.16 |
| rynx-140-148 (ICD) |  |  | 1.62 | 0.42 | 0.83 | 0.302 | 1.27 | 1.69 | 0. 57 | 0.95 | 1.66 | 1.01 | 0.17 | 0.67 | 1.17 | 0.94 | 0.88 | 0. 56 |
| Oesophagus-150 | M | $4 \cdot 81$ | $2 \cdot 16$ | 6.43 | 5.83 | $5 \cdot 13$ | 4. 59 | 4-81 | 6.60 | $5 \cdot 95$ | $8 \cdot 10$ | 9.57 | 9.26 | 13.29 | 15.63 | 15.45 | 15.63 | 14.83 |
|  |  | $2 \cdot 40$ |  | 0.85 | 0.41 | 0. 30 |  | 0. 56 | 0. 29 | 0.71 | 1.24 | 1-22 | 0.89 | 2.86 | $2 \cdot 65$ | 0.80 | 2. 64 | 1.91 |
| Stomach-151 | M | 1. 20 | 2. 16 | 2.14 | $2 \cdot 91$ | $2 \cdot 71$ | 2. 55 | 3. 39 | 2.58 | 3-80 | 2.07 | $2 \cdot 24$ | 1.78 | $2 \cdot 69$ | 2.06 | 1.61 | 1.26 | 1.68 |
|  |  | 1. 20 | $0 \cdot 54$ | 0.42 | 1.66 | 2-11 | 1. 53 | 0.56 | 1.72 | 0.71 | 0.83 | 1.22 | 0.53 | 1.17 | 0.58 | 0.94 | 1.38 | 0.67 |
| Small and large intes- | M |  | 0.54 | - | 0.41 | 0.60 | 1. 20 | 0. 28 | 0.86 | 1. 19 | 0.83 | $0 \cdot 20$ | 0.53 | 0.33 | 1. 32 | 0. 26 | 0.75 | 0.44 |
| $\text { tine }-152-153$ |  |  |  |  | 0.41 | 0. 30 | 0.25 | 0. 56 | 0. 28 | 0.71 | 0.83 | 0.20 | 0.17 | 0.50 | 0.58 | 0. 26 | 0. 50 | 0.44 |
| Rectum-154 | M | 1.20 | 0. 54 | 0.85 |  | 1.51 | 0.51 | 0.84 | 0.86 | 0.71 | 1.03 | 1.42 | 0.17 | 0.16 | 0.14 | 0.67 | 0.88 | 0.67 |
|  | F |  | 0. 54 | 0.85 | 0.83 | 1. 20 | 0.25 | 0.84 | 0.28 | 0.95 | 0.83 | 0.81 | 0.35 | 0.50 | 0.44 | 0.40 | 1.00 | 0.78 |
| Liver and biliary pas- | M | $2 \cdot 40$ | 3-24 | 4. 72 | 5.83 | $7 \cdot 25$ | 5.35 | 7.64 | 6.32 | $7 \cdot 85$ | $8 \cdot 10$ | 6.72 | 8.02 | 6-39 | $4 \cdot 12$ | $4 \cdot 97$ | $6 \cdot 05$ | 5.61 |
| sages-155 |  |  | 0.54 | 0.42 | 0.41 |  | 1.02 | 1. 69 | 0.86 | 0.71 | 1.45 | $2 \cdot 03$ | 0.71 | 0.67 | 1.47 | 1. 20 | 1. 26 | 1.34 |
| Liver secondary and un- |  | - |  |  | 2.50 | 0.60 | 1.02 | 1.41 | 0.86 | 1.42 | 1. 24 | 1.42 | 1. 24 | 0.84 | 0. 44 | 1.07 | 0.88 | 0.89 |
| specified-156 |  |  | 0.54 | 0.42 | 0.83 | 0.60 | 0.51 | 0. 28 | 0.86 | 0.23 | 0.41 | 0.40 | 0.89 | 0. 50 | 0.14 | 1. 20 | 0.37 0.88 | 0. 22 |
| Pancreas-157 | M | 1. 20 | 1.08 |  | 0.83 |  | $0 \cdot 51$ | 0. 28 | 1.43 | 0.95 | 1. 24 | 0.81 | 0.71 | 0.53 | 1.17 | 0.26 0.53 | 0.88 0.75 | 0.56 0.33 |
| Nasal sinuses-160 | M | 2,40 | 1.08 | 0.85 | 0.41 1.66 | 0.30 3.02 | 1.27 | 0.56 0.84 | 0.86 1.43 | 0.71 1.90 | 0.41 1.45 | 0.40 1.22 | 0.53 1.42 | 1.51 | 1.17 1.32 | 0.53 1.74 | 0.88 1.76 | 0.33 1.57 |
|  | F | 1. 20 |  | 1.28 | 0.41 | 1. 20 |  | 0.56 | 0.28 | 0.71 | 0.83 | 0.20 | 1.06 | 0.33 | 0.58 | 0.53 | 0.50 | 0.78 |
| Larynx-161 | M | - | 0. 54 | 0.85 | 0.41 | $0 \cdot 60$ | 1.53 | 0.56 | 0.86 | 1.90 | 1.45 | 0.81 | 1. 60 | 0.84 | 0.88 | 1.47 | 1.38 | 1.01 |
| Bronchus and Jung | M | $2 \cdot 40$ | 0.54 5.94 | 4. 29 | 4.16 | 2-11 | 3.82 | 2.54 | $3 \cdot 44$ | 1.90 | 1.45 | $3 \cdot 86$ | $4 \cdot 27$ | $3 \cdot 87$ | 4.71 | 0.13 5.91 | 4.79 | $5 \cdot 50$ |
| 162 |  | 1.20 |  | 0.85 | 0.41 |  | 0.51 | - 54 | 1-14 | $0 \cdot 71$ | 0.62 | 0.61 | 0.71 | 0.33 | 0. 29 | 0.94 | 0.88 | $0 \cdot 11$ |
| Lung unspecified prim- | M |  | 1.08 | 0.42 |  | 1. 20 |  | 0.28 |  |  | 0.41 | - | - | 0.33 | 0.14 | 0.13 | 0.25 | 0.22 |
| ary or secondary- <br> 163-4-5 |  | - |  |  | - | $0 \cdot 30$ | 0.25 |  | - | 0.47 | 0.20 | - | - |  |  |  | $0 \cdot 12$ | $0 \cdot 11$ |
| Breast-170 |  | 1. 20 |  |  | 0.41 | 0. 30 | 1.27 | $0 \cdot 28$ |  | 0.23 | $0 \cdot 20$ | 0.40 | 0.17 | 0. 33 | 0. 29 | 0.26 | 0.12 | 0.33 |
|  |  | $2 \cdot 40$ | $3 \cdot 24$ | $3 \cdot 43$ | $7 \cdot 08$ | 5.43 | 4.33 | 5.94 | 7.18 | 4. 28 | 4. 57 | 6. 51 | 5.34 | 5. 72 | $4 \cdot 27$ | 5-10 | 3.27 | 5.95 |
| Cervix uteri-171 | F | $27 \cdot 7$ | 23.78 | 24.46 | 18.75 | 21.75 | $28 \cdot 31$ | $24 \cdot 64$ | 20.97 | 25.95 | 20.58 | 21.38 | 21.56 | $20 \cdot 70$ | 20.05 | 18.95 | 17.02 | 16.62 |
| Corpus uteri-172 | F | 1.20 | 1.08 |  | 0.83 | 0.30 |  | 0.56 | 1.43 | 0.71 | 1.45 | 1.22 | 1. 24 | 1.34 | 0.73 | 1. 20 | 0. 50 | 0.89 |
| Chorionepithelioma and other parts of uterus $-173-174$ | F | 1-20 | 1-08 | 0.85 |  | 0.60 | $0 \cdot 25$ | 0.28 | 0. 57 | 0.71 | 0.62 | 0.20 | 0.53 | 0.33 | 0.73 | 0.40 | $1 \cdot 26$ | 0.67 |
| Ovary-175 | F | 1.20 | 3-78 | 0.85 | 1. 25 | 1. 51 | 1.27 | 1.69 | 1.43 | 1-19 | 1.24 | 1.42 | 1. 24 | 1.68 | 1.76 | 1.47 | $2 \cdot 01$ | 1.01 |
| Female genital organs other and unspecified $-176$ | F | 1.20 | 4-32 | 0.85 | 2.91 | 0.30 | 0.25 | 0.28 | 0.86 | 1.42 | 0.83 | 0.61 | 0.89 | 0.84 | 0.88 | 0.80 | $0 \cdot 50$ | 1. 23 |
| Prostate-177 | M | - | 1.08 | 1-28 | 4. 58 | 3-32 | 3-82 | $3 \cdot 68$ | 2.87 | 2-38 | 3-32 | $3 \cdot 66$ | 2-49 | 2. 52 | 3-39 | $3 \cdot 22$ | 2.39 | 2.92 |
| Testis and other male genital organs-178-9 | M | - | 1. 62 | 2.14 | $2 \cdot 08$ | 2-11 | $2 \cdot 04$ | 1.13 | 0.57 |  | $2 \cdot 28$ | 1.01 | 0.53 | 1.85 | 1.91 | 1. 20 | 1.38 | 1.91 |
| Kidney-180 | M | 2.40 | $0 \cdot 54$ | 0.85 | 0.41 | 0.90 | 0.51 | 0.28 | 1. 14 | 0.95 | 0.41 | 0.61 | 0.35 | 0.67 | 0.88 | 0.26 | 0.75 | 0.67 |
|  | M | 1-20 | 1.08 | 0.85 |  |  | 0.76 | 0.56 | 0.28 | 0.71 | 0.20 | 1.22 | 0.71 | 0. 84 | 0.88 | 0.67 | 0.75 | 0.33 |
| Bladder-181 | M | - | $3 \cdot 24$ | 0.85 | $2 \cdot 08$ | 2.41 | 1. 53 | 1.69 | 2.01 | 2.14 | 1.03 | $2 \cdot 24$ | 1.42 | 1.34 | 0. 58 | 1. 20 | 2.01 0.37 | 1.23 |
|  | , | - | $0 \cdot 54$ | 0.42 | 0.83 | 0.90 | 0.25 | 0.56 | 0.28 | 0.23 |  | 1.01 | 0.35 |  | 0.14 |  | 0.37 | 0.56 |
| Skin malignant mela- | M | 1. $\overline{20}$ | 1.62 | 1.28 | 0.83 | 0. 60 | 0.51 | 0. 28 | 0.57 |  | 0.83 | 0.40 | 0.71 | 0. 33 | 0.14 | 0.53 | 0.37 | 0.44 |
| noma-190 | M | 1. 20 | $2 \cdot 16$ | 1.71 | 1.25 | 0.60 | 0.76 | 1.69 | 0.86 | 0.47 | 0.62 | 0.40 | 1.60 | 0.67 | 1.03 | 0.94 | 0.75 | 0.78 |
|  | M | 1-20 | 3-24 | 3.43 | 3. 33 | 3.32 | 1. 27 | 1.41 | 2.29 | 2.14 | 1.24 | 2.03 | 1. 24 | 1.01 | 0.58 | 0.67 | 0.63 | 0.67 |
| plasm of skin-191 | M |  | $2 \cdot 70$ | 2. 57 | 1.25 | 1. 20 | 1.27 | 1.69 | 1.72 | 1.90 | 1.45 | 0.61 | 1. 42 | 0.84 | 0. 88 | 1.20 | 0.63 | 1. 23 |
| Eyes-192 | M | - | - | 0.42 |  | 0.90 | 1.02 | 0.28 | 0.86 | 1.42 | 1. 24 | 0.81 | 0.53 | 1.17 0.50 | 0. 58 | 0.13 0.26 | 0.63 | 0.22 0.33 |
|  |  |  |  | 0.85 | 0.83 | 0. 30 | $0 \cdot 51$ | 0.84 | 0.28 | 0.47 | 1.03 | 0.81 | 1.06 | 0.50 | 0.29 | 0.26 1.33 | 0.12 1.76 | 0.33 1.57 |
| Brain and other parts nervous system-1 | M | 1. 20 | 0.54 0.54 | 0.42 | 0.83 | $0 \cdot 30$ | 1.53 | 0.84 | 2.01 0.86 | 1.66 0.95 | 1.24 0.62 | 1.01 1.42 | 1.42 0.35 | 1.01 1.17 | 1.17 1.17 | 1.33 0.94 | 1.76 0.63 | 1.57 1.12 |
| Thyroid-194 | M | 1. 20 | 0. 54 | 0.85 |  | 0. 30 |  |  | 0. 28 |  | 0.41 |  |  |  | - 29 | $0 \cdot 13$ | 0.12 | 0.11 |
|  | F |  | 1.62 | 1.71 |  | 1. 20 | 0.51 | 0.84 | 0.86 | 0.47 | 0.41 | $0 \cdot 20$ | 1.06 | 0.84 | 1.17 | 0.80 | 0.63 | 0. 56 |
| Bone-196 | M | 1. 20 | $2 \cdot 16$ | 1.28 | 2.08 | 0.30 | 1.27 |  | 0.86 |  | 0.83 | 0. 20 | 1. 24 | 0. 50 | 0.73 | 0. 26 | 0. 25 | 0.67 |
|  | F |  |  | 0.85 | 0.41 | $0 \cdot 90$ | 0.51 | 0.28 | 0.86 | 0.47 | 0.83 | 0.40 | 0.53 | 0. 50 | 0.58 | 0.53 | 0.50 | $0 \cdot 33$ |
| Connective tissue-197 | M | $3 \cdot 61$ | 1.62 | 3.43 | 1. 66 | $3 \cdot 32$ | 1. 53 | 1. 69 | 2.29 | 0.95 | 1.87 | 0.61 | 1. 60 | 1.01 | 1.17 | 1.07 | 1.00 | $2 \cdot 02$ |
|  | F | 1. 20 | 1.08 | 1.28 |  | 0. 30 | 0.51 | 1-13 | 0.86 | 0.95 | 0.83 | 0. 20 | 1.06 | - 50 | 0. 44 | 0.80 | 1.00 | 0.67 |
| Secondary and unspeci- | M | $6 \cdot 02$ | 1.62 | 2. 57 | 1. 66 | 0. 60 | 1. 27 | 1-41 | 0. 57 | 1.19 | 0.83 | 0.61 | 1. 24 | 1.17 | 1.32 | $3 \cdot 09$ | 2-14 | 2. 47 |
| fied lymph glands or generalized-198-9 | F | - | 1 | 0.42 | 0.41 | 0.90 | $2 \cdot 29$ | 0.84 | 0.86 | 0.47 | 0.62 | 0.20 | 1.78 | 1.51 | 0 - 8 | 2-01 | 1.38 | 1.79 |
| Lymphosarcoma and | M | 2.40 | 1.08 | $3 \cdot 00$ | 0.41 | 0.90 | 0.76 | $0 \cdot 28$ | 1-14 | 0.95 | 0.62 | 0.61 | 0.71 | $1 \cdot 17$ | 0. 58 | 1.33 | . 2. | 0.68 |
| reticulosis- 200 | F | 1. 20 | 0.54 | 1.28 | 0.83 | 0.90 | 0.51 | 1.98 | 0. 57 | 0.47 | 0.41 | 1. 62 | 0.89 | 0.67 | 0.29 | 0.13 | 0.25 | 0.22 |
| Hodgkin's disease-201 | M | 1.20 | 1.08 | 0.85 | 0.41 | 1. 20 | 1.02 | 1.41 | 0.86 | 1.19 | 1.66 | 0.81 | 0-17 | 1-01 | 0. 58 | 0.67 | 0.88 | 0.78 |
|  | F |  | 0.54 | 0.42 | 0.41 |  | 0.51 | 0.28 | $0 \cdot 28$ | 0.23 | $0 \cdot 20$ | $0 \cdot 20$ | 0.17 | 0.67 | 0.44 | 0.40 | 0.12 0.37 | 0.22 0.89 |
| Other lymphoma-202 | M | - | - | - | 0.41 | 0. 30 | 0. 25 | 0.28 | 0. 57 |  | 0.62 | 0.61 | 0.71 | 0. 33 | 0.88 | 0.26 0.26 | 0.37 0.50 | 0.89 |
| Multiple myeloma-203 | F | - | 1.08 | 0.85 | 0.83 | 0.30 0.60 | 0.25 1.53 | 0.28 0.28 | 0.28 0.28 | 0.23 0.47 | 0.62 0.41 | 0.61 1.01 | 1.06 | 0.16 0.33 | 0.88 0.58 | 0.26 0.80 | 0.50 0.63 | 0.11 0.11 |
|  | F |  | 0. 54 |  |  | - 6 | 0.51 | 0.84 | 0.86 | 0.47 | 0.20 | 0.20 | 0.35 | 0.50 | 0.14 | 0.13 | 0.75 | $0 \cdot 11$ |
| Leukaemia-204 | M | $3 \cdot 61$ | 1.62 | 0.85 | 1.66 | 1. 51 | 2.04 | $2 \cdot 54$ | 0. 28 | 1.66 | 1. 66 | 0.61 | 0.71 | 0.67 | 1.47 | 0.94 | 0. 50 | 1.01 |
|  |  |  | 1.08 |  | 0.41 | $0 \cdot 60$ | 0.25 | 1.13 | $2 \cdot 01$ | 0.71 | 0.41 | 0.40 | 0.53 | 0.84 | 0. 58 | 0.80 | 0.88 | 0.33 |
| Mycosis fungoides-205 | M | - | - | - | - | - | $0 \cdot 25$ | - | 0.28 | - | - |  | - | - | 0.14 | - | - | 0.11 |

table v. total cancers by Sex, 1948-1964


TABLE VIA. TOTAL CANCERS FOR 1960 EXPRESSED AS INCIDENCE (PER 100,000) OF POPULATION AT RISK IN TRANSVAAL BETWEEN AGES 25 AND 69 YEARS

|  | Population at risk |  |
| :--- | ---: | ---: |
|  | Males | Females |
| Total population | $1,067,573$ | 801,216 |
| Total cases | 236 | 231 |
| $\quad$ Incidence | $22 \cdot 1$ | $28 \cdot 8$ |
| Cases (excluding breast and genital) | 220 | 65 |
| Incidence | $20 \cdot 6$ | 8.1 |
| Cases breast and genital | 16 | 166 |
| $\quad$ Incidence | 1.5 | 20.7 |

Table VII shows a series of random sites by age and sex-oesophagus, stomach, lung and bronchus, larynx (with an almost complete lack of involvement in females) and breast. All these showed the maximum number of cases in the 45-54-year age-group, with slight minor variations, in both males and females. This age frequency is supported by reference to hospital admissions (Table I), as there is no commensurate increase in admissions at the ages indicated. This age factor also applied to connective tissue and the haematopoietic and lymphatic cancers.

TABLE VIB. CANCER AS SEX INCIDENCE PER 100,000 AT DIFFERENT SITES AT RISK IN TRANSVAAL EXPRESSED AS AN anNual average over 17 Years

| Site | ICD Code No. Male | Female |  |
| :--- | :---: | :---: | :---: |
| Oesophagus | 150 | $4 \cdot 2$ | .68 |
| Stomach | 151 | .90 | .49 |
| Liver | 155 | $2 \cdot 34$ | .57 |
| Larynx | 161 | .45 | .01 |
| Lung | 162 | $1 \cdot 67$ | .27 |
| Skin | 191 | .55 | .54 |
| Thyroid | 194 | .07 | .31 |
| Connective tissue | 197 | .54 | .27 |
| Lymphatic and haemato- |  |  |  |
| $\quad$ poietic | $200-204$ | $1 \cdot 19$ | .80 |
| Breast | 170 | - | $3 \cdot 8$ |
| Cervix | 171 |  | 16.02 |

Thyroid cancer showed an unequal sex distribution, but in the reverse ratio, and also the increasing number of male cases in the older age-groups. This would suggest a possible hormonal association.
'Cervical' cancer showed a greater incidence over a wider age range as the maximum numbers were in the 35-54-year age-group.

Table VIII demonstrates that the maximum number of
table vil. Random Cancers at different sites by age, 1960-1964

|  |  | Male |  |  |  |  |  |  |  |  | Female |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Code No. | 15-19 | 20-24 | 25-34 | 35-44 | 45-54 | 55-64 | 65-74 | $75+$ | N/S | 15-19 | 20-24 | 25-34 | 35-44 | 45-54 | 55-64 | 65-74 | $75+$ | $N / S$ |
| Oesophagus | 150 | - | 2 | 40 | 166 | 291 | 181 | 101 | 46 | 5 | - | 3 | 7 | 24 | 37 | 11 | 15 | 12 | - |
| Stomach | 151 |  | - | 19 | ${ }_{13}^{33}$ | 58 14 | 33 | 22 | ${ }_{3}^{6}$ | 2 | 1 | - | 2 | 15 | 18 | 14 | 15 | 8 |  |
| Large intestine | 153 | 2 | $\overline{2}$ | 2 | ${ }^{13} 8$ | 14 | $1{ }^{7}$ | ${ }_{6}^{4}$ | 3 | 1 | 1 | - | $\frac{2}{4}$ | 14 | 11 | 7 | 5 | 1 |  |
| ${ }_{\text {Liver }}$ | 155 | 12 | 17 | 87 | 134 | 111 | 63 | 30 | 16 | 5 | 1 | 2 | 10 | 15 | 19 | 22 | 12 | 3 | 2 |
| Pancreas | 157 |  |  | 5 | 5 | 18 | 17 | 8 | 4 |  | - | - | 2 | 4 | 8 | 8 | 6 | 6 |  |
| Larynx | 161 |  | - | 3 | 17 | 35 | 21 | 8 | 3 |  |  | - | 2 | 1 |  |  |  |  |  |
| Bronchus | 162 | - | 2 | 9 | 53 | 120 | 78 | 44 | 13 | 3 | 2 |  | , | 102 | 7 | 8 | 5 | 2 |  |
| ${ }_{\text {Breast }}$ | 170 | - | 1 | - | 3 | 5 | 5 | 5 | 4 | 1 | - | 7 | 41 | 102 | 113 | 65 | 43 | ${ }_{56} 4$ |  |
| ${ }_{\text {M }}{ }_{\text {Melanix }}$ | 190 | 7 | $\frac{1}{2}$ | ${ }_{5}$ | $\overline{2}$ |  |  | 5 |  |  |  | 12 | 24 | 45 | 11 | ${ }^{16}$ | 140 | ${ }_{8}^{86}$ | 10 |
| Skin | 191 | 4 | 1 | 25 | 25 | 22 | 19 | 10 | 2 | 2 | 9 | 9 | 14 | 18 | 14 | 14 | 14 | 9 |  |
| ${ }_{\text {Brain }}^{\text {Pran }}$ | 193 |  |  | 17 | 20 | 19 | 3 | 3 | 2 |  | ${ }^{4}$ | 8 | $\stackrel{11}{8}$ | 4 | 11 | 13 | $\bigcirc$ | 2 | $\frac{1}{3}$ |
| ${ }_{\text {Thyroid }}$ | 194 |  |  |  | $\frac{2}{7}$ | ${ }_{9}^{3}$ | 6 | 2 | 二 | 二 | ${ }_{8}^{2}$ | ${ }_{4}^{5}$ | 8 | 7 | 10 5 | 13 3 | 5 | 6 |  |
| Connective tissue | 197 | 3 | 4 | 19 | 25 | 29 | 14 | 12 | 3 | 2 |  | 5 | 16 | 8 | 6 | 5 | 2 | 2 | - |
| Lymphatic + | 200 | 14 | 21 | 48 | 77 | 39 | 35 | 18 | 11 | 4 | 13 | 11 | 23 | 25 | 29 | 20 | 12 | 6 | 3 |
|  |  | 49 | 65 | 297 | 590 | 796 | 504 | 278 | 121 | 27 | 43 | 72 | 412 | 721 | 750 | 478 | 300 | 150 | 19 |

table viil. primary liver Cancer (155) by sex and age

| Year | Male |  |  |  |  |  |  |  | Female |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 15-19 | 20-24 | 25-34 | 35-44 | 45-54 | 55-64 | 65-74 | 75+ | 15-19 | 20-24 | 25-34 | 35-44 | 45-54 | 55-64 | 65-74 | $75+$ |
| 1948 |  |  | 1 | 1 |  |  |  |  |  |  |  |  |  |  |  |  |
| 1949 | 1 | 1 | 3 |  |  | 1 | 1 |  |  |  |  |  | 1 |  |  |  |
| 1950 |  | 1 | 4 | 3 | 2 |  |  |  |  |  | 1 |  |  |  |  |  |
| 1951 | 2 |  | 1 | 4 | 2 | 1 | 1 |  |  |  |  |  | 1. |  |  |  |
| 1952 |  |  | 3 | 9 | 7 | 3 | 1 | 1 |  |  |  |  |  |  |  |  |
| 1953 |  | 1 | 7 | 9 | 2 | 1 | 1 |  | 1 | 1 |  | 1 |  |  |  |  |
| 1954 |  | 3 | 3 | 10 | 6 | 3 |  | 1 |  |  | 1 |  |  | 3 | 2 |  |
| 1955 | 2 |  | 3 | 6 | 7 | 2 | 2 |  |  |  | 1 | 1 |  |  | 1 |  |
| 1956 | 2 | 1 | 6 | 7 | 5 | 6 | 3 | 2 |  |  | 1 | 1 | 1 |  |  |  |
| 1957 |  | 3 | 5 | 11 | 8 | 7 | 4 | 1 |  |  |  | 3 | 3 | 1 | 2 |  |
| 1958 |  |  | 3 | 9 | 8 | 8 | 2 | 2 |  |  |  | 2 | 4 | 1 | 1 | 1 |
| 1959 | 2 | 3 | 8 | 16 | 4 | 4 | 2 | 2 |  |  |  |  |  | 6 |  |  |
| 1960 |  | 1 | 5 | 14 | 9 | 5 | 3 | 2 |  |  | 1 | 1 | 1 |  |  |  |
| 1961 |  |  | 10 | 5 | 7 | 7 |  |  |  | 1 | 2 | 1 | 2 |  | 1 |  |
| 1962 | 2 | 1 | 9 | 7 | 12 | 3 | 3 |  |  |  | 2 | 1 | 2 | 2 | 1 | 2 |
| 1963 |  | 1 | 6 | 15 | 14 | 5 | 3 | 4 |  |  | 1 | 4 |  | 2 | 2 |  |
| 1964 | 1 | 1 | 10 | 8 | 18 | 7 | 4 | 1 |  |  |  |  | 4 | 6 | 2 |  |
|  | 12 | 17 | 87 | 134 | 111 | 63 | 30 | 16 | 1 | 2 | $\overline{10}$ | $\overline{15}$ | 19 | 22 | 12 | 3 |

Age of five males and two females unspecified.

| Year | Hepatoma | Carcinoma gallbladder | Cholangiocarcinoma |
| :---: | :---: | :---: | :---: |
| 1960 | 26 | 4 | - |
| 1961 | 30 | 3 | - |
| 1962 | 30 | 3 | - |
| 1963 | 35 | 3 | 1 |
| 1964 | 35 | 9 | 1 |

table x. occurrence of Carcinoma of liver (155) by monthly incidence to indicate any possible seasonal influence (due to Storage of food, etc.) as by month of first symptom


TABLE XI. LIVER CANCER SURVIVAL RATE FROM DATE OF FIRST SGGN TO DEATH, 1952-1964

| Length of survival from first symptom | 1952 | 1953 | 1954 | 1955 | 1956 | 1957 | 1958 | 1959 | 1960 | 1961 | 1962 | 1963 | 1964 | Total |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Males |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 0-3 months | 10 | 13 | 17 | 12 | 16 | 18 | 10 | 10 | 19 | 13 | 19 | 17 | 18 | 192 |
| 3-6 months | 7 | 4 | 2 | 3 | 5 | 4 | 7 | 6 | 3 | 5 | 4 | 7 | 7 | 64 |
| 6-9 months | 1 |  | 2 |  | 2 | 2 | 1 | 2 |  | I | 1 | 1 | 2 | 15 |
| 9-12 months | 1 |  |  |  |  |  |  | 1 |  | 1 |  |  |  | 3 |
| 12-15 months |  |  | 1 | 1 | 1 |  | 1 |  | 1 | I | 1 | 1 | 1 | 9 |
| 15 months-2 years |  |  |  |  |  |  |  | 1 |  | 1 |  |  |  | 2 |
| Death date unknown | 4 | 4 | 5 | 4 | 7 | 13 | 10 | 15 | 16 | 10 | 11 | 16 | 22 | 137 |
| Fermales |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 0-3 months |  | 1 | 3 | 2 |  |  |  | 3 | 1 |  | 2 | 4 | 6 | 22 |
| 3-6 months |  |  | 1 |  | 1 | 1 | 2 | 1 | 1 | 2 | 1 |  | 3 | 13 |
| 6-9 months |  |  |  |  |  |  |  |  |  |  |  |  | 1 | 1 |
| 9-12 months |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 12-15 months |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| 15 months-2 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Death date unknown |  |  | 3 | 1 |  | 4 | 7 | 1 | 1 | 2 | 3 | 4 | 1 | 27 |

table Xil. Cases of Cancer of liver and oesophagus by age and sex indicating survival rate from first symptom TO DEATH FOR 1960-1964


TABLE XIII. RANDOM TABLE OF SURVIVAL TIMES AT VARIOUS SITES FROM FIRST SYMPTOM OR SIGN TO DATE OF DEATH (1952-1964)

|  | Male |  |  |  | Female |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Length of survival to death | Oesophagus | Pancreas | Ca. lung | Haematopoietic andlymphatic | Oesopha- gus | Pancreas | Ca. lung | Cervix | Haematopoietic and lymphatic |
| 0- 3 months | 165 | 20 | 45 | 52 | 23 | 10 | 10 | 88 | 44 |
| 3-6 months | 146 | 10 | 34 | 23 | 14 | 4 | 7 | 85 | 13 |
| 6-9 months | 74 | 1 | 20 | 17 | 9 | 2 | 1 | 63 | 4 |
| 9-12 months | 32 | - | 10 | 6 | 3 | 1 | 1 | 34 |  |
| 12-15 months | 14 | - | 11 | 4 | 3 | - | - | 44 | 3 |
| 15-18 months |  | - |  |  |  | - |  | 13 | - |
| 11-2 years | 8 | - | 1 | 2 | 2 | 1 | 3 | 14 | - |
| $>2$ years | 18 | - | 11 |  | 3 | - | - | 17 |  |
| $>3$ years | - | - | - | 2 | - | - | - | 8 | 3 |
| $>4$ years | - | - |  | - | - | - |  | 3 |  |
| Details not complete | 342 | 19 | 153 | 175 | 43 | 16 | 15 | 1.073 | 86 |



Fig. 1. Cancer incidence expressed as a percentage of the total annual cancer admissions.
cases of liver cancer occurred in a somewhat earlier agegroup in males than in females. It indicates the increasing susceptibility in males with a possible association with liver dysfunction and/or cirrhosis. This host difference could be connected with hormone imbalance and alterations in liver metabolism.

Table IX indicates the histological type of liver cancer found in the years 1960-1964. Frequent pathological reports were 'postnecrotic cirrhosis of liver with hepatocellular carcinoma'. This would seem to indicate the recovery of a necrotic liver from an earlier stage of damage, either
by an external toxin or by a carcinogen, and suggests probable damage to a cell or actual mutant cell formation.

Table X shows that cancer of the liver was not related to a possible seasonal exhibition of carcinogen as has been suggested. ${ }^{1}$

Table XI shows the survival rate in malignant hepatoma from the first sign or presenting symptom, and not the date of hospital admission. The majority of patients were dead within 6 months of the first symptoms.

It would appear that there is a sudden diminution in host resistance and that once unrestrained carcinogenesis


Fig. 2 (a). Incidence of cancer of the nasal sinuses, larynx, bronchus and lung expressed as a percentage of the total cancer admissions.


Fig. 2(b). Actual number of cases observed annually.


Fig. 3(a). Incidence of cancer of the oesophagus, buccal cavity, pharynx and stomach expressed as a percentage of the total cancer admissions.
sets in, the disease runs a rapid course.
Table XII gives the survival rates for liver and oesophageal cancers for the years 1960-1964. The rate of growth of the tumours did not appear to be related to the age or sex of the patient.

Table XIII gives the survival rates for a series of random sites and suggests that once the host resistance is overcome, very rapid growth of the cancer takes place. The high number of cases with 'details or date of death unknown' are mainly due to the preference of the majority of patients (if fit enough) to return to relatives in remote areas of the country, where follow-up study is obviously impracticable. In fact, this practice is encouraged after palliative treatment has been completed. These findings appear to indicate the trend to rapid development once host control is released.

A recent article giving details of a $99 \%$ 'follow-up' of nearly 400 cases of carcinoma of the oesophagus showed that only 2 patients had survived 2 years-one of whom died in the 25 th month-and only 10 more than 1 year. In fact, $90 \%$ were dead within 6 months of admission. ${ }^{4}$

## Relationship of Cancers to Population

According to the 1960 population census $42.95 \%$ of
males and $37.41 \%$ of females were between the ages of 25 and 69 years, and yet $79 \cdot 18 \%$ of cancers occurred in this age-group. The populations at risk under the age of 25 years and over the age of 70 years were $57.05 \%$ for males and $62.59 \%$ for females, and the cancer incidence in these groups was $20 \cdot 82 \%$.

This shows clearly that the predominating number of cancer cases occur between 25 and 69 years, and this is evident in the cancer admissions (most dying before 70 years). The increasing numbers are also emphasized by the smaller population at risk (between 25 and 69 years) although cancer continues to play a major role in the diminishing population over 70 years of age.

## Observations on Figures

The figures shown below emphasize the trends indicated in the tables. Figs. 1-5 compare the rates and actual numbers of cases annually for various sites-showing sex differences.

Fig. 1 represents cancer admissions expressed as a percentage of total annual cancer admissions. This is really a facet of Table IV which is condensed to show the variations of cancers of the oesophagus, cervix, lung, bronchus and liver in males and females. It will be noted


Fig. 3(b). Actual number of cases observed annually.
that the relative percentage of cancer of the cervix declined and that there was a steep rise in male cancer of the oesophagus, whereas the female oesophagus cancer rate remained relatively stable. The percentages of lung and bronchial cancers showed a slight increase in males, but none in females. The percentage of primary liver cancer seems to have passed the peak, but has been unaccompanied by a commensurate rise in the female percentages.

Fig. 2 is a representation of the annual cancer rates occurring in cancer of the nasal sinuses, cancer of the larynx and cancer of the lung and bronchus in males and females. It suggests that simple inhalation of carcinogens will not explain the differences, unless the susceptible tissues in the nasal passages, larynx, bronchus and lung react differently to the external carcinogens to which they are exposed; for the differences are too marked to be coincidental. In addition the sex differences in each site, particularly lung and bronchus, would suggest differing host susceptibility or resistance rather than differences in exposure to carcinogens.

Fig. 3 shows a similar pattern, suggesting that ingestion of carcinogens must involve differences in tissue susceptibility, for the buccal cavity, pharynx, oesophagus and stomach are not similarly affected. It would also appear
that, apart from differences at the site exposed, there is a difference between male and female host involvement in cancer of the oesophagus.

Fig. 4 indicates great differences in incidence between malignancies of the cervix uteri, corpus uteri and ovary, suggesting an environmental agent in the case of the cervix differing from that of the corpus uteri and ovary.

Fig. 5 shows the sex differences in cancer of the liver and biliary passages. This suggests differences in host and tissue susceptibility, especially as in Table VIII it appears to occur in different age-groups.

## GENERAL OBSERVATIONS

It must be made clear that these statistics and figures apply to a non-White hospital in Johannesburg and have no direct relevance to the Johannesburg White population. One obvious feature seems to be the marked difference between the sexes, and the preponderant number of cases at most sites which occur in the 45-54-year age-group together with the rapidly fatal termination from onset of symptoms, even though the exhibition of carcinogens is unlikely to be at uniform ages or doses. This could involve the removal of host restraint, enabling the latent
or dormant damaged or mutant cancer cell or cells to develop.

These observations on a Bantu hospital population confirm that host resistance varies with sex. Carcinogens appear to have some degree of specificity for certain tissues. Malignancies appear in greater numbers in certain age-groups and a large proportion of clinical cancers show rapid unrestricted growth followed by the patient's death, not directly related in set time or dose to carcinogenic exhibition, suggesting a release of control of latent mutant cells.


Fig. 4(a). Incidence of cancer of the cervix, corpus uteri and ovary expressed as a percentage of the total cancer admissions.

## Relationship to Transvaal Population

Further observations relating to the Transvaal population at risk are shown in the following tables and figures, using years 1960-1964 as examples. Some interesting facts are apparent.

The adaptation of incidence rates of cases from a single hospital is, of course, not possible because all cancers are not admitted to one hospital, but population numbers can still be compared at different ages as they apply to the ages of hospital admissions and the Transvaal population, making them comparable as confirmed in Table XIV. They are on different standards to incidence although in proportion. They are expressed as one in 10,000 to draw attention to the fact that they are not 'incidence'.


Fig. 4(b). Actual number of cases observed annually.

Table XIV and Fig. 6 give the population of the Transvaal by 5-year age-groups for the ages $25-69$ years, with sex differences, based on the figures of the 1960 census. This represents the steep fall of a population with a shorter life-span than the White population.

Table XV and Fig. 7 indicate that the cancer rate in the Transvaal per 10,000 has a gradual increase up to 50 years of age, diminishes during the next few years and thereafter again increases rapidly in the following ageing population up to 60 years.

Table XVI and Fig. 8 show a dip in the curve after $\pm 50$ years of age when cases are expressed as a percentage of the total annual cancers and also the following

## LIVER CANCER 1948-64 IN MALES \& FEMALES EXPRESSED

 AS \% LIVER CANCERS TO TOTAL CANCER ADMISSIONS ANNUALLY

Fig. $5(a)$. Incidence of cancer of the liver expressed as a percentage of the total cancer admissions.


Fig. 5(b). Actual number of cases observed annually.
table Xiv. population census 1960 of transvaal showing percentage male, female and total in age-groups

|  | Age-groups (years) |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 |
| Males | 9.51 | $7 \cdot 80$ | $7 \cdot 02$ | $5 \cdot 96$ | $4 \cdot 89$ | $3 \cdot 14$ | $2 \cdot 20$ | 1.44 | 0.92 |
| Females | $8 \cdot 13$ | $6 \cdot 92$ | $5 \cdot 89$ | $4 \cdot 97$ | 3.74 | 2.84 | 1.94 | 1.76 | $1 \cdot 18$ |
| Males + females | $8 \cdot 87$ | $7 \cdot 40$ | $6 \cdot 50$ | $5 \cdot 50$ | 4.36 | $3 \cdot 01$ | 2.08 | 1.59 | 1.04 |
| Total 1960 hospital admissions as percentage by age | $12 \cdot 4$ | $12 \cdot 0$ | $9 \cdot 1$ | $8 \cdot 0$ | $7 \cdot 0$ | $5 \cdot 1$ | $2 \cdot 6$ | $3 \cdot 0$ | 1.6 |

Males under 25 and over 70 years: $1,418,055(57.05 \%)$. Males between 25 and 69 years: $1,067,573(42 \cdot 89 \%$ ).
Females under 25 and over 70 years: $1,340,591(62 \cdot 53 \%)$. Females between 25 and 69 years: $801,216(37 \cdot 37 \%)$.


Fig. 6. Population of the Transvaal by 5 -year age-groups for the ages $25-69$ years, based on the figures of the 1960 census.
temporary rise in the diminishing admissions in the older age-groups.

Table XVII and Fig. 9 show the annual rate per 10,000 of the Transvaal population, with breast and genital organs expressed separately because of their very different behaviour.

These tables and figures show that there is an increasing susceptibility or diminishing host resistance to cancer and that maximum numbers occur at about 50 years, after which diminution of susceptibility (or increased resistance) in the next 5 years takes place, followed again by increasing susceptibility (or diminished host resistance) in the 60-65-
table XV. incidence cancer cases to population at risk in transvaal by age and sex groups ( $1: 10,000$ ) (1960 census)

|  | Age-groups in years |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 |
| Males 50-54 50-59 - 50-60 - |  |  |  |  |  |  |  |  |  |
| Yearly average Ca. cases (1960-1964) | $9 \cdot 6$ | $21 \cdot 0$ | $28 \cdot 2$ | $46 \cdot 8$ | $54 \cdot 0$ | $57 \cdot 6$ | $32 \cdot 6$ | $44 \cdot 4$ | $26 \cdot 8$ |
| Transvaal population by agegrouping (1960) | 236,621 | 194,092 | 174,709 | 148,258 | 121,665 | 78,273 | 54,907 | 36,001 | 23,047 |
| Per 10,000 | $0 \cdot 405$ | 1.08 | 1.61 | $3 \cdot 15$ | 4.43 | $7 \cdot 35$ | $5 \cdot 93$ | $12 \cdot 34$ | $11 \cdot 62$ |
| Females Pr |  |  |  |  |  |  |  |  |  |
| Yearly average Ca . cases (1960-1964) | $13 \cdot 0$ | $30 \cdot 4$ | $34 \cdot 6$ | $39 \cdot 2$ | $40 \cdot 2$ | $38 \cdot 6$ | $22 \cdot 4$ | $29 \cdot 2$ | 17-2 |
| Transvaal population by agegrouping (1960) | 174,283 | 148,383 | 126,174 | 106,405 | 80,105 | 61,017 | 41,650 | 37,734 | 25,465 |
| Per 10,000 | 0.745 | $2 \cdot 04$ | $2 \cdot 74$ | $3 \cdot 68$ | $5 \cdot 01$ | $6 \cdot 32$ | $5 \cdot 37$ | $7 \cdot 73$ | $6 \cdot 75$ |



Fig. 7. Incidence of cancer to Transvaal population at risk based on the figures of the 1960 census.
year group and then a lower number of cases in the ageing population. It would seem to be that some effective check is applied temporarily on the cancer risk, possibly by hormonal imbalance. This temporary decrease in susceptibility would seem to be difficult to reconcile with the exposure and delayed onset of cancer involving a purely carcinogenic dose-time exposure theory.

AVERAGE \% ANNUALLY OF ALL CANCERS FOR 5 YEARS


Fig. 8. Age incidence of all cancer cases observed at Baragwanath Hospital during the 5 years 1960-1964.

## INTERPRETATION AND SUGGESTED HYPOTHESIS

Clinically the host-tumour relationship of cancer has continually attracted attention and has recently received increasing recognition.

The specificity of carcinogens to certain tissues is known and also their association with certain sites, but the delay in onset of cancer and apparent latency have been unexplained.

TABLE XVI. CASES EXPRESSED AS \% OF TOTAL ANNUAL CANCER CASES AT BARAGWANATH HOSPITAL BY AGE-GROUPING (1960-1964)

|  | Age-group in years |  |  |  |  |  |  |  |  | Total for year |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | 65-69 |  |
| 1960 number | 20 | 43 | 59 | 59 | 67 | 64 | 55 | 62 | 38 | 594 |
| \% of total | 3.3 | $7 \cdot 2$ | $9 \cdot 9$ | $9 \cdot 9$ | $11 \cdot 2$ | $10 \cdot 7$ | $9 \cdot 2$ | 10.4 | $6 \cdot 3$ |  |
| 1961 number | 18 | 36 | 56 | 82 | 84 | 90 | 61 | 65 | 39 | 678 |
| \% of total | $2 \cdot 6$ | $5 \cdot 3$ | $8 \cdot 2$ | $12 \cdot 0$ | $12 \cdot 3$ | $13 \cdot 2$ | $8 \cdot 9$ | $9 \cdot 5$ | 5.7 |  |
| 1962 number | 25 | 60 | 47 | 81 | 105 | 112 | 49 | 81 | 37 | 744 |
| \% of total | $3 \cdot 3$ | $8 \cdot 0$ | $6 \cdot 3$ | $10 \cdot 8$ | $14 \cdot 1$ | $15 \cdot 0$ | $6 \cdot 5$ | $10 \cdot 8$ | $4 \cdot 9$ |  |
| 1963 number | 23 | 61 | 69 | 98 | 103 | 110 | 45 | 73 | 47 | 793 |
| \% of total | $2 \cdot 9$ | $7 \cdot 6$ | $8 \cdot 7$ | $12 \cdot 3$ | 12.9 | 13.8 | $5 \cdot 6$ | $9 \cdot 2$ | 5.9 |  |
| 1964 number | 27 | 57 | 83 | 110 | 112 | 105 | 65 | 87 | 59 | 890 |
| $\%$ of total | $3 \cdot 0$ | $6 \cdot 4$ | $9 \cdot 3$ | $12 \cdot 3$ | $12 \cdot 5$ | 11.7 | $7 \cdot 3$ | $9 \cdot 7$ | $6 \cdot 6$ |  |
| Total | 113 | 257 | 314 | 430 | 471 | 481 | 275 | 368 | 220 | 3,699 |
|  | $3 \cdot 0$ | $6 \cdot 9$ | $8 \cdot 4$ | $11 \cdot 6$ | $12 \cdot 7$ | $13 \cdot 0$ | $7 \cdot 4$ | $9 \cdot 9$ | $5 \cdot 9$ | 3,699 |

$20 \cdot 8 \%$ of all cases $(770)$ were under 25 years and over 70 years: $1960-127$ cases $(21 \cdot 3 \%) ; 1961-147$ cases $(21 \cdot 6 \%) ; 1962-147$ cases $(19 \cdot 7 \%) ; 1963-164$ cases $(20 \cdot 6 \%)$ and $1964-185$ cases ( $20 \cdot 7 \%$ ).

TABLE XVIIA. AVERAGE ANNUAL CANCER RATE (PER 10,000) EXCLUDING BREAST AND GENITAL TO TRANSVAAL POPULATION AT RISK (1960-1964)

|  | Age-group in years |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Male |  |  |  |  |  |  |  |  |  |
| Total 1960-1964 | 47 | 102 | 136 | 212 | 261 | 268 | 151 | 195 | 108 |
| Average annual | $9 \cdot 4$ | $20 \cdot 4$ | $27 \cdot 2$ | $42 \cdot 4$ | $52 \cdot 2$ | $53 \cdot 6$ | $30 \cdot 2$ | 39.0 | 21.6 |
| Population at risk | 236,621 | 194,092 | 174,709 | 148,258 | 121,665 | 78,273 | 54,907 | 36,001 | 23,047 |
| Rate | 0.397 | $1 \cdot 05$ | $1 \cdot 55$ | $2 \cdot 85$ | $4 \cdot 29$ | 6.84 | $5 \cdot 50$ | $10 \cdot 83$ | $9 \cdot 37$ |
| Female |  |  |  |  |  |  |  |  |  |
| Total 1960-1964 | 30 | 44 | 54 | 67 | 59 | 59 | 37 | 49 | 28 |
| Average annual | $6 \cdot 0$ | $8 \cdot 8$ | $10 \cdot 8$ | $13 \cdot 4$ | 11.8 | 11.8 | $7 \cdot 4$ | $9 \cdot 8$ | $5 \cdot 6$ |
| Population at risk | 174,283 | 148,383 | 126,174 | 106,405 | 80,105 | 61,017 | 41,650 | 37,734 | 25,465 |
| Rate | 0.344 | 0.593 | $0 \cdot 855$ | $1 \cdot 25$ | 1.47 | 1.93 | $1 \cdot 77$ | 2. 59 | $2 \cdot 19$ |
| Male + female |  |  |  |  |  |  |  |  |  |
| Total 1960-1964 | 77 | 146 | 190 | 279 | 320 | 327 | 188 | 244 | 136 |
| Average annual | $15 \cdot 4$ | 29.2 | $38 \cdot 0$ | $55 \cdot 8$ | $64 \cdot 0$ | 65.4 | $37 \cdot 6$ | $48 \cdot 8$ | $27 \cdot 2$ |
| Population at risk | 410,904 | 342,475 | 300,883 | 254,663 | 201,770 | 139,290 | 96,557 | 73,735 | 48,512 |
| Rate | 0.374 | 0.852 | $1 \cdot 26$ | $2 \cdot 19$ | $3 \cdot 17$ | $4 \cdot 69$ | $3 \cdot 89$ | $6 \cdot 62$ | $5 \cdot 60$ |

TABLE XVIIB. AVERAGE ANNUAL RATE (PER 10,000) BREAST AND GENITAL CANCERS BY AGE TO TRANSVAAL POPULATION AT RISK (1960-1964)

|  | Age-group in years |  |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Male | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-49 | 60-64 | 65-69 |
| Total 1960-1964 | 1 | 3 | 5 | 14 | 7 | 18 | 10 | 27 | 26 |
| Average annual | $0 \cdot 20$ | 0.60 | $1 \cdot 0$ | $2 \cdot 8$ | $1 \cdot 4$ | $3 \cdot 6$ | $2 \cdot 0$ | $5 \cdot 4$ | $5 \cdot 2$ |
| Population at risk | 236,621 | 194,092 | 174,709 | 148,258 | 121,665 | 78,273 | 54,907 | 36,001 | 23,047 |
| Rate | $0 \cdot 0084$ | $0 \cdot 0309$ | 0.0572 | 0-188 | $0 \cdot 115$ | $0 \cdot 459$ | 0.364 | 1.49 | $2 \cdot 25$ |
| Female 1960 (1964 |  |  |  |  |  |  |  |  |  |
| Total 1960-1964 | 35 | 108 | 119 | 140 | 144 | 126 | 77 | 96 | 58 |
| Average annual | $7 \cdot 0$ | $21 \cdot 6$ | $23 \cdot 8$ | $28 \cdot 0$ | $28 \cdot 8$ | $25 \cdot 3$ | $15 \cdot 4$ | $19 \cdot 2$ | 11.6 |
| Population at risk | 174,283 | 148,383 | 126,174 | 106,405 | 80,105 | 61,017 | 41,650 | 37,734 | 25,465 |
| Rate | 0.40 | 1.45 | 1.88 | $2 \cdot 63$ | $3 \cdot 59$ | 4-14 | $3 \cdot 69$ | $5 \cdot 08$ | $4 \cdot 55$ |
| Male + female |  |  |  |  |  |  |  |  |  |
| Total 1960-1964 | 36 | 111 | 124 | 154 | 151 | 144 | 87 | 123 | 84 |
| Average annual | $7 \cdot 2$ | $22 \cdot 2$ | $24 \cdot 8$ | $30 \cdot 8$ | $30 \cdot 2$ | $28 \cdot 8$ | 17.4 | 24.6 | $16 \cdot 8$ |
| Population at risk | 410,904 | 342,475 | 300,883 | 254,663 | 201,770 | 139,290 | 96,557 | 73,735 | 48,512 |
| Rate | $0 \cdot 17$ | $0 \cdot 648$ | 0.824 | $1 \cdot 21$ | 1.49 | $2 \cdot 06$ | 1.80 | $3 \cdot 33$ | 3.46 |

It has not yet been established whether the cell (or cells) exists in a damaged, vulnerable but still viable form, or whether it is already a mutant cell in a dormant state before malignant changes are established.

The suggestion, based on clinical observations, is tentatively put forward that this state might be linked, as indicated by sex differences and age incidence, to possible hormone imbalance, whereby a mutant or malignant
cell is released from restraint and, still capable of mitotic development and survival, develops (partially controlled, or uncontrolled) at a rapid rate. The occasional delay in the onset of secondaries is probably related to a relative increase of resistance following removal of the primary, and later, hormone imbalance releasing the latent cancer cell. This is indicative of a 'dormant' cancer cell, the revival process being superficially the opposite of the


Fig. $9($ a $)$. Average annual incidence of cancer per 10,000 of the Transvaal population, excluding cancer of the breast and genital organs.
tissue rejection factor of transplantation.
It would appear that a genetic, or constitutional, component is involved with a deficiency or excess of the resistance factor so influencing the time of onset. This could account for the early or late cases, the non-development after exposure to carcinogens, the enzymal detoxification of carcinogens, perhaps even a carcinogen combining with, and so neutralizing, the resistance factor, and also rejection of cancer in situ, or many of the established racial differences-and other apparent anomalies. Genetic influence is apparent in retinoblastoma.

Another possible clinical example of this, observed in the cases, is that of renal tumours (Table XVIII) suggesting one genetic in origin, with early susceptibility, and the other later in onset, by loss of resistance.

Could this be of adrenal origin-with imbalance of hypo-, hyper- or abnormal secretion? The known influences on growth of cortisone, particularly in stimulating cancers and also in retarding the rejection of tissue transplants and impairing resistance to bacterial or viral invasion, as well as the temporary beneficial effects of adrenalectomy on metastases, are recognized effects.

Other hormone imbalances where cancer is involved with androgens and oestrogens in relationship to certain cancers (breast and prostate) are probably all interrelated with corticosteroid action.

## SUMMARY

A survey of the clinical distribution of cancer cases at Baragwanath Hospital over 17 years was undertaken, showing cancer rates by site, sex and age. The difference in susceptibility of males and females at the similar sites has been noted as evidence of host resistance. The tissue susceptibility and the tissue specificity of external carcinogens for differing sites are confirmed.


Fig. 9 (b). Average annual incidence of cancer of the breast and genital organs per 10,000 of the Transvaal population.

TABLE XVIII. KIDNEY TUMOURS (180): WILM'S AND HYPERNEPHROMA BY AGE AND SEX

|  |  | Male |  | Female |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Year | Total No. of cases | Wilm's | Hypernephroma adenocarcinoma + sarcoma | Wilm's | Hypernephroma adenocarcinoma + sarcoma | Wilm's average age per annum | Hypernephroma average age per annum |
| 1948 | 3 | 1 | 1 | - | 1 | 2 years | 59 years |
| 1949 | 3 | - | 1 | 1 | 1 | 4 months | 59 years |
| 1950 | 3 | 1 | - | 1 | 1 | 4 months | 50 years |
| 1951 | 1 | - | 1 | - | - | - | 35 years |
| 1952 | 2 | - | 2 | - | - | - | 36 years |
| 1953 | 5 | - | 2 | 1 | 2 | $2 \frac{1}{2}$ years | 37 years |
| 1954 | 3 | - | 1 | 2 | - | $8 \frac{1}{2}$ months | 43 years |
| 1955 | 5 | 2 | 2 | 1 | - | 3 years | 44 years |
| 1956 | 5 | 2 | 1 | 1 | 1 | $5 \frac{1}{2}$ years | 34 years |
| 1957 | 3 | 1 | 1 | 1 | - | 4 years | 60 years |
| 1958 | 6 | 2 |  | 1 | 2 | 7 years | 65 years |
| 1959 | 6 | - | 2 |  | 3 | 2 years | 41 years |
| 1960 | 8 | - | 4 | 2 | 2 | 9 months | 66 years |
| 1961 | 11 | 1 | 4 | 3 | 3 | 4 years | 48 years |
| 1962 | 6 | - | 2 | 2 | 2 | $1 \frac{1}{2}$ years | 57 years |
| 1963 | 9 | - | 4 |  | 3 | 4 years | 41 years |
| 1964 | 9 | 3 | 3 | 1 | 2 | 5 years | 45 years |
| Total | 88 | 13 | 32 | 20 | 23 |  |  |

Other clinical observations are made on the increasing number of cases at certain ages, suggesting altering host resistance. This is followed on release of control by a relatively uniform rapid growth, suggesting that host-tumour relationship has been modified allowing a presumed dormant cell to develop uncontrollably.

The inference is that the host-tumour relationship is partially controlled by hormone imbalance.

I wish to thank Dr W. H. F. Kenny, Medical Superintendent of Baragwanath Hospital, for permission to undertake this survey, and $\operatorname{Dr}$ A. Schmaman for access to the pathology records. I am also indebted to the late Dr A. G. Oettlé who suggested this survey but unfortunately died in the early stages before having an opportunity to assemble the datahis analysis would indeed have been very valuable.

I should also like to thank Mr Haywood, of the registry at Baragwanath Hospital, for his help and adequate record keeping; Mr C. Mabaso for his assistance with extraction of the bed letters; and Mesdames D. Vickery, A. Woolford and J. Doody for their untiring assistance in transcribing and recording details from numerous sources.

## REFERENCES

1. Higginson, J. and Oettlé, A. G. (1960): J. Nat. Cancer Inst., 24, 589.
2. Oettlé, A. G. (1964): Ibid., 33, 383.
3. World Health Organization (1957): Manual of the International Statistical Classification of Diseases, Injuries and Causes of Death, 7th revision, vol. 1, p. 75. Geneva: WHO.
4. De Moor, N. G. (1968): S. Afr. Med. J., 43, 892.

[^0]:    -Date received: 19 November 1968

